Document is current
Any future updates will be listed below
-
Authors
Ely, Zackery A.
Mathey-Andrews, Nicolas
Naranjo, Santiago
Gould, Samuel I. https://orcid.org/0000-0003-2617-5215
Mercer, Kim L. https://orcid.org/0000-0002-8525-483X
Newby, Gregory A. https://orcid.org/0000-0001-7869-2615
Cabana, Christina M.
Rideout, William M. III
Jaramillo, Grissel Cervantes
Khirallah, Jennifer M.
Holland, Katie
Randolph, Peyton B. https://orcid.org/0000-0001-6385-364X
Freed-Pastor, William A.
Davis, Jessie R.
Kulstad, Zachary
Westcott, Peter M. K.
Lin, Lin
Anzalone, Andrew V.
Horton, Brendan L.
Pattada, Nimisha B.
Shanahan, Sean-Luc
Ye, Zhongfeng
Spranger, Stefani
Xu, Qiaobing https://orcid.org/0000-0001-7323-7795
Sánchez-Rivera, Francisco J. https://orcid.org/0000-0002-8466-8563
Liu, David R. https://orcid.org/0000-0002-9943-7557
Jacks, Tyler https://orcid.org/0000-0001-5785-8911
-
Funding
Funding for this research was provided by:
Lustgarten Foundation
U.S. Department of Health amp; Human Services | National Institutes of Health (F31CA268835)
- License Information
-
More Information
Article History
Received: 15 July 2022
Accepted: 5 April 2023
First Online: 11 May 2023
Competing interests
: T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics. T.J. is also the President of Break Through Cancer. None of these affiliations represent a conflict of interest with respect to the design or execution of this study or the interpretation of data presented in this manuscript. His laboratory currently receives funding from the Johnson & Johnson Lung Cancer Initiative, but this funding did not support the research described in this manuscript. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine, and Nvelop Therapeutics, companies that use or deliver genome editing or genome engineering agents, and owns equity in these companies. K.H. and A.V.A. are currently employees of Prime Medicine. The remaining authors declare no competing interests.
